TGFB1 and cancer: Cancer-secreted TGF-β is capable of inducing CAF phenotype [111,112,113], and TGF-β signalling in CAFs is closely linked to poor clinical outcome [94,114], with inhibition leading to remodelling of CAF dynamics, better immune response, and disease regression in in vitro models.